Athira had clung to the hope that its experimental drug fosgonimeton could overcome a phase 2 failure in Alzheimer’s to demonstrate success in Parkinson’s and dementia. Unfortunately, a mid ...

Leen Kawas resigned as Athira's CEO in October 2021 after an investigation into her doctoral work. She's now forging a new path with a life sciences investment firm and telling her side of the story.

Stressing the importance of integrity in taxpayer-funded biomedical research, the U.S. Department of Justice reported that Athira Pharma Inc. agreed to pay more than $4 million to resolve False Claims ...